Small Cap

Auto Added by WPeMatico

CBD Products Gain Attention as Chronic Pain Incidences Rises

NEW YORK, Feb. 11, 2019 /PRNewswire/ — Chronic pain is among one of America’s most commonly present medical conditions. Within the U.S., approximately 70 million suffered from moderate to high levels of chronic pain in 2016, according to data by the National Health Interview Survey. As a result, many were prescribed opioids as a treatment to mitigate the pain. However, in the long run, the mass prescription of opioids had resulted in an epidemic. In 2017, there were 47,600 cases related to opioid overdose which resulted in death out of the reported 70,200 overall overdose incidents. The rising number of cases prompted many countries to pass medical cannabis laws in order to reduce the number of people dependent on opioids. The therapeutic effects of cannabis are known to suppress pain, but are also linked to treating other medical cases such as cancer and epilepsy. Although, due to the lack of large-scale clinical trials, cannabis is not yet recognized as medicinal by the U.S. Food and Drug Administration. Now however, many companies are pouring investments in the industry to further develop the research and global expansion of cannabis. According to data compiled by Verified Market Intelligence, the global marijuana market was valued at USD 42.20 Billion in 2017 and is projected to reach USD 466.81 Billion. Additionally, the market is expected to grow at a CAGR of 35.3% throughout the forecast period from 2018 to 2025. Weekend Unlimited Inc. (OTC:WKULF) (CSE:POT), VIVO Cannabis Inc. (OTC:VVCIF), Nightfood Holdings, Inc. (OTC:NGTF), MYM Nutraceuticals Inc. (OTC:MYMMF) (CSE:MYM), PotNetwork Holdings, Inc. (OTC:POTN)

Despite the issue of federal legality revolving around medical cannabis, there are currently 33 states and the District of Columbia that have legalized cannabis for medical use. States are also allowing the use of many cannabis derivatives, such as CBD (cannabidiol), CBN (cannabinol) and THC (delta-9-tetrahydrocannabinol). CBD is one of the fastest growing segments in the cannabis market because it is the non-psychoactive derivative of cannabis and companies involved in both the medical and recreational markets are using CBD within their products. Hemp-derived CBD’s effects had even prompted government regulators to remove it from the list of Schedule 1 drugs, even though other cannabis components like THC still remain on the list. “CBD has a number of known properties beneficial to the human condition, and research is just beginning,” Aster Farms President Sam Ludwig told Civilized. “There are two markets for CBD: as a supplement, mild pain reliever and relaxant, and in larger doses, as a truly beneficial remedy for a variety of serious illnesses. There is no doubt it will be dominant supplement for years to come.”

Weekend Unlimited Inc. (OTC:WKULF) also listed on the Canadian Securities Exchange under the ticker (CSE:POT). Earlier this morning the company announced breaking news that, “announces the appointment of Mr. Karl Schmieder, MS/MFA., to the role of Director, Business Development and Tom Wisniewski, Vice President Sales Operations. As an executive and entrepreneur, Mr. Schmieder brings more than 25 years of business development success in biopharmaceutical and internet industries. Mr. Wisniewski brings more than 20 years of sales expertise in consumer-packaged goods, investment, real estate, telecommunications industries.

“Karl is a strategic thinker who will contribute to the development of new products, partnerships and services. Tom brings diverse leadership experience in sales and operations and will help drive our national and international growth,” said Mr. Paul Chu, President and Chief Executive Officer, Weekend Unlimited. “The addition of Karl and Tom helps strengthen Weekend’s management as we execute our growth strategy,” added Mr. Chu.

Mr. Schmieder co-founded messagingLAB, a strategy and marketing communications firm focused on the life sciences. He has successfully launched biotechnology companies and pharmaceutical products and services. He has held executive and business development positions at emerging digital health and leading strategy communications consulting firms.

Mr. Wisniewski is seasoned sales professional with extensive experience nationally and internationally. He has served as managing director of Rocket Holdings, a private investment and real estate group. In addition, Mr. Wisniewski served as field account manager at VHA Corporation and sales manager at Abmnus. Mr. Wisniewski is a pioneer in …

Full story available on Benzinga.com

CBD Market Could Outpace Entire Marijuana Market

Financialnewsmedia.com News Commentary

PALM BEACH, Florida, Feb. 7, 2019 /PRNewswire/ — In the horse race to revenues, it seems that CBD infused products market may outpace the cannabis market, with the passage of the 2018 Farm Bill kicking it ahead across the finish line! A report from a cannabis industry analyst, as reported in The Rolling Stone magazine, says: “For years, experts have predicted that if the cannabis industry expands at its current rate, the American market will reach $20 billion by 2020. But it turns out that one market is spinning off into a mega-industry of its own: according to a new estimate from cannabis industry analysts the Brightfield Group, the hemp-CBD market alone could hit $22 billion by 2022.” In fact the Rolling Stone sub-headline sums it up the reason why: “Looking forward to relaxed hemp regulations, a new analysis estimates that the CBD market could explode — and outpace marijuana.”. Previously, CBD products have been available mostly in head shops, with a few doctors recommending it for various maladies. But in 2017 and 2018, the products spread to natural food stores, beauty aisles, cafés and doctors offices. So far the industry is on track to hit $591 million in 2018, and thanks to a number of factors — including, surprisingly, Senate Majority Leader Mitch McConnell — that could increase 40 times in the next four years.”   Active companies in the markets this week include The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF), Aphria Inc. (NYSE:APHA) (TSX:APHA), Harvest Health & Recreation Inc. (CSE:HARV) (OTC:HRVOF), 1933 Industries Inc. (CSE:TGIF) (OTC:TGIFF), MedMen Enterprises Inc. (CSE:MMEN) (OTC:MMNFF).

“According to the (Brightfield’s) projections, there would be increases in just about every sector that sells CBD — from dispensaries to smoke shops to medical companies. But perhaps the biggest push, according to Gomez, would be from big-box retailers and national chains who have been eager to get in on the lifestyle craze but have felt stifled by the (older )regulations (that have been replaced by the passage of The 2018 Farm Bill.”

The Yield Growth Corp.

 (CSE:BOSS) (OTCPK:BOSQF)

BREAKING NEWS

   Yield Growth Corp is pleased to announced that its e-commerce platform will now sell its Urban Juve cannabis Sativa hemp root oil-based products in the United States thanks to the adoption of the 2017 U.S. Farm Bill.  

Urban Juve products are now available for sale in the U.S. via the site www.urbanjuve.com.  In addition, the company has plans to sell its products through U.S. retailers such as pharmacies, naturopaths, clinics, salons, spas, wellness and beauty stores.

“U.S. distribution is a cornerstone of our sales strategy for all our brands. Already we have a deal in place to sell our THC and CBD infused products through …

Full story available on Benzinga.com

FinancialBuzz.com Exclusive Interview With Chairman and CEO Denis Corin of Q BioMed Inc. Live From Times Square in New York City

NEW YORK, Feb. 5, 2019 /PRNewswire/ — www.FinancialBuzz.com, a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with Q Biomed Inc. (OTCQB:QBIO) Chairman and CEO, Denis Corin from the floor of the NASDAQ MarketSite at Times Square New York City.

Mr. Corin shares with us his vision of Company’s growth and why he believes 2019 and beyond are essential years for Q BioMed Inc. The interview provides unique insight into the Company’s latest corporate developments, updates on recently-achieved milestones, and current upcoming catalyst. Additionally, Mr. Corin provides his perspective on how Q BioMed Inc. is well positioned to build upon its current pipelines and creating continued shareholder value.

Mr. Denis D. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD: TPIV), a clinical stage immune -oncology company through 2014, He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.

Watch the full HD Video Interview now to learn more about the buzz surrounding Q BioMed Inc. (OTCQB:QBIO)

Click Here for full HD video interview: https://www.youtube.com/watch?v=ZsmRFGNBeI8&t=6s

About Q BioMed Inc. (www.qbiomed.com)

Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company’s FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019.  Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of …

Full story available on Benzinga.com